Meeting
2022 ASCO Genitourinary Cancers Symposium
Criteria used to determine platinum eligibility and first-line (1L) treatment (tx) patterns among platinum-eligible (PE) and -ineligible (PI) patients (pts) with metastatic urothelial cancer (mUC) in France, Germany, Spain, Italy, and the United Kingdom (Eu5).
Authors
Neil Milloy
Adelphi Real World, Bollington, United Kingdom
Neil Milloy , Melissa Kirker , Mia Berry , Michael Kostikas , Rachel Montgomery , Mairead Kearney , Nuno Matos Costa , Jane Chang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 457)
DOI
10.1200/JCO.2022.40.6_suppl.457
Abstract #
457
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
US real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval.
First Author: Haojie Li
Poster
2018 ASCO Annual Meeting
Phase II randomized study of first line avelumab with carboplatin-gemcitabine versus carboplatin-gemcitabine alone in patients with metastatic urothelial carcinoma ineligible for cisplatin-based therapy.
First Author: Alejo Rodriguez Vida
Poster
2024 ASCO Genitourinary Cancers Symposium
Evolving treatment landscape in metastatic urothelial carcinoma (mUC) post-avelumab maintenance approval: Real-world insights from The US Oncology Network.
First Author: Haojie Li
Poster
2023 ASCO Quality Care Symposium
Real-world overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) systemic therapy (tx): Results from IMPACT UC II.
First Author: Mehmet Asim Bilen